Introduction
============

Because of its ability to block late INa \[[@B1]\], ranolazine is used as an antianginal agent for the treatment of chronic angina pectoris when angina is not adequately controlled by other agents \[[@B2]\]. Besides its cardiovascular effects, ranolazine improves different neuronal functions, and thus its use has been proposed for the treatment of pain and epileptic disorders \[[@B3],[@B4]\]. Since astrocytes are involved in neuronal inflammatory processes, and autoimmune and neurodegenerative diseases \[[@B5]\], we have investigated the antiinflammatory and antioxidant effects of ranolazine in primary cultured astrocytes.

Methods
=======

We incubated differentiated rat astrocytes in primary culture (10 days of culture) \[[@B5]\] for 24 hours with ranolazine (10^-5^, 10^-6^, 10^-7^M). We measured the protein expression levels of PPARy and Cu/Zn-SOD by western blot technique. Protective effect of ranolazine on cell viability was assayed using MTT conversion assay. Finally, to evaluate the effect of ranolazine on the IL-1β cytokine and TNFα mediators, we used the enzyme-linked immunosorbent assay technique.

Results
=======

Compared with control cells, treatment with ranolazine induced an increment of anti-inflammatory PPARy and reduced the proinflammatory mediators IL-1 β and TNFα in primary cultured astrocytes. Ranolazine (10^-6^M) also increased the expression of antioxidant protein Cu/Zn-SOD and caused a significant increase in cell viability.

Conclusion
==========

Ranolazine decreases inflammatory mediators IL-1 β and TNFα, and increases anti-inflammatory PPARy as well as the antioxidant Cu/Zn-SOD in astrocytes in culture. These results suggest that ranolazine could be useful as a neuroprotective drug in pathologies inducing inflammatory damage and oxidant processes.
